Tecentriq is an immunotherapy medicine for several cancers, including lung cancer and liver cancer. It is given as an infusion into a vein, or as a shot under the skin in a version called Tecentriq Hybreza. It works by taking the brakes off the immune system so it can find and attack cancer cells.
Every report comes from a Lived member, sent anonymously.
Have you tried Tecentriq (Atezolizumab) for Non-Small Cell Lung Cancer?
Atezolizumab, sold as Tecentriq, is an immunotherapy medicine used to treat several cancers. It belongs to a group of drugs called immune checkpoint inhibitors. A second product, Tecentriq Hybreza, contains the same antibody combined with hyaluronidase, an enzyme that allows it to be given as an injection under the skin instead of through a vein. Its largest role is in lung cancer. For non-small cell lung cancer, the most common type, it can be given alone after surgery and chemotherapy to lower the chance of stage II to IIIA cancer returning when the tumor tests positive for a protein called PD-L1. When the tumor has no EGFR or ALK gene changes, it is also used as a first treatment for lung cancer that has spread, either alone when PD-L1 levels are high or together with chemotherapy for the non-squamous type. It can be used later on when platinum chemotherapy (a standard type that includes cisplatin and carboplatin) has stopped working. For extensive-stage small cell lung cancer, meaning cancer that has spread beyond one area of the chest, it is given with chemotherapy as a first treatment and can then be continued with lurbinectedin, another chemotherapy drug. Outside the lungs, it is approved with bevacizumab (Avastin), a drug that blocks the growth of the blood vessels tumors need, as a first treatment for advanced liver cancer (hepatocellular carcinoma); with two targeted pills, cobimetinib and vemurafenib, for advanced melanoma that carries a BRAF V600 gene change; and for alveolar soft part sarcoma, a rare soft tissue cancer. It can also be given after surgery to lower the chance of cancer coming back in two situations. The first is muscle-invasive bladder cancer after the bladder has been removed, when a blood test still finds tumor DNA (circulating tumor DNA, a sign that cancer cells remain in the body). The second is stage III colon cancer whose tumor a laboratory test shows is mismatch repair deficient (dMMR), meaning its cells cannot fix certain errors made when they copy their DNA; here it is given together with chemotherapy. Children can receive it for the sarcoma and for that type of colon cancer: the IV form from age 2, and the under-the-skin form from age 12 if they weigh at least 40 kg (about 88 pounds). Each use depends on the cancer's stage and often on a tumor or blood test result, so having one of these cancers does not by itself make someone a candidate.
The immune system has built-in brakes, called checkpoints, that keep T cells (white blood cells that destroy infected or abnormal cells) from attacking the body's own tissues. One of these brakes is a protein called PD-L1. Many tumors, and immune cells around them, display PD-L1, which switches off T cells that would otherwise attack the cancer. Atezolizumab is a lab-made antibody that attaches to PD-L1 and blocks that signal, so T cells can recognize and attack cancer cells again. It does not kill cancer cells directly; the immune system does that work. Because the same brakes also protect healthy organs, releasing them can lead the immune system to attack normal tissue as well, which is the source of most of the drug's serious side effects.
Atezolizumab is always given by a health professional in a clinic or infusion center. Tecentriq goes into a vein as an infusion. The first infusion takes about 60 minutes, and later ones can be shortened to 30 minutes if the first goes smoothly. Adults usually receive it every 2, 3 or 4 weeks, with the dose matched to the schedule, and the care team picks the schedule that fits the rest of the treatment plan. Children receive a dose based on their weight. Tecentriq Hybreza is injected under the skin of the thigh over about 7 minutes every 3 weeks. Its dose differs from the IV product, so the two are not swapped milligram for milligram. When atezolizumab is combined with chemotherapy or bevacizumab, it is usually given first on the same day. For melanoma, the two pills are taken for about four weeks before atezolizumab is added. After surgery for lung or bladder cancer, treatment lasts up to one year; for cancer that has spread, it usually continues as long as it is helping and side effects remain manageable. If an appointment is missed, call to reschedule as soon as possible.
With atezolizumab alone, the most common effects are tiredness or weakness, reduced appetite, nausea, cough and shortness of breath. When it is combined with other cancer drugs, some effects come mainly from the partner treatment: hair loss and constipation with lung cancer chemotherapy, high blood pressure and protein in the urine with bevacizumab, rash, joint pain and sun sensitivity with the melanoma pills, and numbness or tingling in the hands and feet with colon cancer chemotherapy. The serious risk is that the released immune system attacks healthy organs. This is uncommon for any one organ, but it can become severe or life-threatening. Call the care team right away if signs like these appear, grouped here by the organ involved: Lungs: new or worsening cough, chest pain or shortness of breath. Bowel: diarrhea, blood or mucus in the stool, or severe belly pain. Liver: yellow skin or eyes, dark urine, or pain on the right side of the belly. Hormone glands: headaches that will not go away, extreme tiredness, unusual hunger or thirst, urinating more often, or dizziness or fainting. These are easy to put down to cancer or its treatment, so they are worth reporting too. Kidneys: less urine, blood in the urine or swollen ankles. Skin: a widespread rash, blistering or peeling skin, or painful sores in the mouth or genital area. Nerves and muscles: new tingling or numbness in the arms or legs, or muscle weakness that is severe or does not go away. Getting treatment early helps keep these problems from becoming more serious. Care usually means pausing or stopping atezolizumab and giving corticosteroids to calm the immune response, or giving hormone replacement when a gland stops making enough of a hormone. Infusion reactions affect about 1 in 100 people and can include chills or shaking, flushing, itching, wheezing or feeling faint. They usually start during the infusion, when staff can slow or stop it; report one that begins after you leave.
Before starting, tell the care team if you have an autoimmune disease such as Crohn's disease, ulcerative colitis or lupus; have had an organ or tissue transplant, including a cornea transplant; have had or are planning a stem cell transplant from a donor; have had radiation to the chest; or have a nerve condition such as myasthenia gravis or Guillain-Barré syndrome. Atezolizumab can cause rejection of a transplanted organ, lung inflammation is more common after chest radiation, and a donor stem cell transplant before or after treatment carries a risk of serious complications such as graft-versus-host disease, in which donor cells attack the body. These histories do not always rule treatment out, but they change the balance of risk. The care team should also know about every other medicine, vitamin and supplement you take. Atezolizumab can harm a developing baby. People who could become pregnant should have a pregnancy test before starting, use effective birth control during treatment and for at least 5 months after the last dose, and tell the care team right away about a known or possible pregnancy. Breastfeeding is not advised during treatment or for 5 months after the last dose. The drug may also affect female fertility, which is worth raising before treatment begins.
Treatment follows a regular schedule of clinic visits. Blood tests before and during treatment check liver, kidney and thyroid function, and scans are used to judge how the cancer is responding. Because atezolizumab works through the immune system, responses vary widely: some cancers shrink, some stop growing for a time, and some keep growing. In the trials behind its approvals, adding it to chemotherapy for extensive-stage small cell lung cancer extended median survival (the point at which half the people in a trial group were still alive) from about 10 months to about 12 months. In advanced liver cancer, 29% of people given it with bevacizumab had died when the results were analyzed, compared with 39% of those given the oral drug sorafenib. After surgery for stage III dMMR colon cancer, the cancer returned or the person died in 13% of those who received it with chemotherapy, compared with 23% of those who had chemotherapy alone, at the time the results were analyzed. Immune side effects can begin at any point, including after treatment has ended, so new symptoms are worth reporting even months after the last dose. Some, such as thyroid problems, are managed with hormone replacement medicine rather than by stopping cancer treatment for good.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Tecentriq (Atezolizumab), what you've noticed, or ask the community a question.